Biomarkers help researchers predict treatment response, disease risk, or recurrence. Trials increasingly incorporate biomarker endpoints to accelerate drug development and improve patient selection.

Recent work shows blood-based molecular markers can predict cancer recurrence risk and survival outcomes, demonstrating how biomarker-guided trials can shape future treatment strategies. These approaches allow earlier intervention and more personalized treatment pathways.